Chapter 32. Dyslipidemia in Chronic Kidney Disease

  1. Donald A. Molony MD2,3 and
  2. Jonathan C. Craig MD, PhD4,5
  1. Vera Krane MD and
  2. Christoph Wanner MD, PhD

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch32

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Krane, V. and Wanner, C. (2008) Dyslipidemia in Chronic Kidney Disease, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch32

Editor Information

  1. 2

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 3

    Houston Medical School, Houston, Texas, USA

  3. 4

    School of Public Health, University of Sydney, Australia

  4. 5

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • low-density lipoprotein (LDL) cholesterol;
  • dyslipidemia in CKD;
  • dyslipidemia and impact on CVD;
  • lipid-lowering therapy in CKD patients;
  • CKD stage V - dialysis;
  • assessment and diagnosis of dyslipidemia;
  • isolated low HDL cholesterol


This chapter contains sections titled:

  • Introduction

  • Types of dyslipidemia in different stages of chronic kidney disease and renal replacement therapy

  • Dyslipidemia and impact on CVD

  • Cardiovascular end point studies on lipid-lowering therapy in CKD patients

  • Renal end point studies of lipid-lowering therapy in CKD patients

  • Treatment guidelines

  • References